June 23, 2021Regeneron Pharmaceuticals, Inc. • November 3rd, 2022 • Pharmaceutical preparations
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Regeneron Pharmaceuticals, Inc. • November 3rd, 2022 • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 03 hereby amends Project Agreement No. 01 as follows:
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Regeneron Pharmaceuticals, Inc. • November 3rd, 2022 • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 06 hereby amends Project Agreement No. 01 as follows:
Reference: MCDC Base Agreement No. 2020-504 Dear :Regeneron Pharmaceuticals, Inc. • November 3rd, 2022 • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 02 hereby amends the Base Agreement as follows:
